CRSP Stock Performance, Insider Transaction and News

CRSP - CRISPR Therapeutics AG

Market Cap	4.18B	P/E	-	EPS this Y	-190.70%	Ern Qtrly Grth	-
Income	-217.14M	Forward P/E	-7.69	EPS next Y	16.30%	50D Avg Chg	-10.00%
Sales	271.71M	PEG	0.05	EPS past 5Y	-	200D Avg Chg	-
Dividend	N/A	Price/Book	2.25	EPS next 5Y	-200.40%	52W High Chg	-37.00%
Recommedations	2.40	Quick Ratio	17.72	Shares Outstanding	84.92M	52W Low Chg	36.00%
Insider Own	1.86%	ROA	-7.97%	Shares Float	78.82M	Beta	1.79
Inst Own	71.12%	ROE	-11.03%	Shares Shorted/Prior	14.59M/14.76M	Price	53.01
Gross Margin	-83.50%	Profit Margin	-79.92%	Avg. Volume	1,274,458	Target Price	84.50
Oper. Margin	-27,894.25%	Earnings Date	May 8	Volume	1,470,467	Change	-6.03%

Healthcare | Biotechnology | Switzerland

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG News

05/17/24	BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
05/17/24	Is CRISPR Therapeutics Stock a Buy?
05/15/24	Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
05/14/24	2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
05/13/24	15 Best ARK Stocks To Buy Now
05/13/24	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
05/13/24	The 3 Best Cathie Wood Stocks to Buy in May 2024
05/11/24	The 3 Most Undervalued Biotech Stocks to Buy in May 2024
05/11/24	Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higher
05/10/24	CRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst Net Income Forecast
05/10/24	We're Interested To See How CRISPR Therapeutics (NASDAQ:CRSP) Uses Its Cash Hoard To Grow
05/09/24	CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
05/09/24	CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
05/08/24	CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
05/08/24	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
05/08/24	CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
05/06/24	CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
05/04/24	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
05/03/24	CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
05/03/24	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar

CRSP Chatroom

burbs88 Posted - 3 hours ago

$CRSP https://www.science.org/content/article/nih-and-gates-foundation-lay-out-ambitious-plan-bring-gene-based-treatments-hiv-and Once again, way down the road, but never say never

burbs88 Posted - 3 hours ago

$CRSP Way down the road, but there are reasons to believe CRSPR theraputics will be at the forefront.

CuchulainnPrimus Posted - 4 hours ago

$CRSP https://www.statnews.com/2024/05/17/arc-institute-generative-ai-crispr/

Auto_MA_T_Ka Posted - 15 hours ago

CRISPR Therapeutics $CRSP this week closed above its best respected 5-week SMA resistance line for the first time since it was first broken in March. $VRTX $NTLA $EDIT $BEAM -- 📉Find the BEST Respected Moving Average Support & Resistance Lines📈

Wigglyick Posted - 18 hours ago

@S2b good luck, $CRSP chart looks like it’s gonna move back up.

S2b Posted - 18 hours ago

@Wigglyick I just got out of that one. Moving on to $CRSP

Curculese Posted - 18 hours ago

@vince20 give it time brother…. Turning $1k to $40k is going to take some time… give it 3 years. $CRSP

Clargy Posted - 19 hours ago

$CRSP ST bottom candidate working its way through stage 1

svertical1 Posted - 21 hours ago

$CRSP $EDIT $VRTX $NTLA $TNYA Which companies are best positioned for this pace of discovery? CRSP, NTLA, EDIT, BEAM, TNYA https://youtu.be/W4_xG9sxX7A?si=VCY4z8Rmaln2u9l6 Big question, can FDA keep up?

JohnPDaly Posted - 21 hours ago

$BTC C. $LCTX $CRSP Retail grinds out the yards but institutions score the touchdowns. Stay in the game, lads.

Spydemic Posted - 1 day ago

$CRSP

topstockalerts Posted - 1 day ago

Why Cathie Wood’s ARK Innovation ETF is struggling in 2024 despite the stock-market rally $ARKK $ROKU $RBLX $CRSP https://www.marketwatch.com/story/why-cathie-woods-ark-innovation-etf-is-struggling-in-2024-despite-a-rally-in-u-s-stocks-e6155496?mod=home-page

Gary6474 Posted - 1 day ago

$CRSP Wow it didn't close near it's lows for once

BoeingStingray Posted - 1 day ago

Deaf baby can hear after 'mind-blowing' gene therapy treatment | Live Science $crsp https://www.livescience.com/health/genetics/deaf-baby-can-hear-after-mind-blowing-gene-therapy-treatment

BoeingStingray Posted - 1 day ago

How Gene Editing Therapies Could Go Beyond Rare Diseases $crsp https://www.forbes.com/sites/juergeneckhardt/2024/05/16/how-gene-editing-therapies-could-go-beyond-rare-diseases/

phonystark Posted - 1 day ago

$CRSP this looks like such a good buy here

Capitulation_0 Posted - 2 days ago

$PRME More exciting that $CRSP, $NTLA

SodApOp_PIMP Posted - 2 days ago

$CRSP 52 buy order open gtc

mstan Posted - 2 days ago

$CRSP we know where we should go but man when it makes set up you need to have a strong stomach 😂

Stawks12 Posted - 2 days ago

$BLUE here is the real juice. BLUE had a net revenue of $18.6million last quarter and $CRSP had a net revenue of $504k. No reason this shouldn’t be at $10. BULLISH bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well https://finance.yahoo.com/news/bluebird-blue-tops-q1-sales-173400845.html

SeeTheFuture Posted - 2 days ago

$TXG Crazy quiet in here. Not long entered and around 8% down. Not concerned as it's a starter position and I'm well aware this could track lower for a good while yet. That said...if people smarter than me are buying it I'm okay holding for the long term to see how this all plays out. Future looks bright on a long timeline. I'll buy more if it gets below $20 but I'm in as this could reverse for the long term at anytime. No matter how it pans out here I'm happy to support the genetic revolution. $ILMN $CRSP $NTLA

AlphaRR Posted - 2 days ago

@jjames_ I was curious where Inscaled out on $EDIT 76 , 34 , 22 and 18 It wasn't a big position $NTLA I timed well And dumped most at 138 Whey edit over $crsp

AlphaRR Posted - 2 days ago

@jjames_ wow that's $5 huh I owned that and sold a very long time ago I owned all 3 top Ticked $NTLA , sold edit a little Late but not to bad , held $CRSP all these years , eh we will see if that works out long term

Dios890 Posted - 2 days ago

$CRSP added.

BoeingStingray Posted - 2 days ago

$CRSP — Just launched into five new trials (in vivo). They’ve got a drug to market and the oncology franchise will be $10B a year opportunity. The company is diverse and purposeful in its endeavors. Long

Thelonius_Stonk Posted - 3 days ago

$CRSP prob pulls a big gap n go over 59 soon or going to 40s lol

BarneyR Posted - 3 days ago

$BEAM $EDIT $NTLA $CRSP $VERV The assholes are now in full regalia. Taking advantage of low volume to drive the whole gene therapy sector down.

BarneyR Posted - 3 days ago

$CRSP $BEAM $EDIT $NTLA $VERV The scummy crew showed up early today, 3 minutes in. Usually they'll give in 15 or 20 minutes before they launch their little games. Concerned that gene therapy shares are gaining momentum?

JuliaWarhol15 Posted - 3 days ago

$CRSP

BIGT80 Posted - 3 days ago

$CRSP added more premarket!

Analyst Ratings

Oppenheimer	Outperform	May 10, 24
JMP Securities	Market Outperform	May 9, 24
Wells Fargo	Equal-Weight	May 9, 24
Cantor Fitzgerald	Neutral	May 9, 24
Barclays	Equal-Weight	May 9, 24
Needham	Buy	May 9, 24
Baird	Neutral	May 9, 24
Citigroup	Buy	Apr 18, 24
Needham	Buy	Apr 11, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jan 29	Sell	60.8	50,000	3,040,000	187,377	01/31/24
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jan 29	Option	19.12	50,000	956,000	237,377	01/31/24
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	May 30	Sell	65.13	25,000	1,628,250	387,377	06/01/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	May 30	Option	19.12	25,000	478,000	412,377	06/01/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Apr 25	Sell	50.97	25,000	1,274,250	387,377	04/27/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Apr 25	Option	19.12	25,000	478,000	412,377	04/27/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Mar 29	Sell	44.58	25,000	1,114,500	387,377	03/31/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Mar 29	Option	19.12	25,000	478,000	412,377	03/31/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Feb 27	Sell	48.49	25,000	1,212,250	375,988	03/01/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Feb 27	Option	19.12	25,000	478,000	400,988	03/01/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jan 27	Sell	51.07	25,000	1,276,750	369,111	01/31/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jan 27	Option	19.12	25,000	478,000	394,111	01/31/23
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Dec 28	Sell	41.13	25,000	1,028,250	369,111	12/30/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Dec 28	Option	19.12	25,000	478,000	394,111	12/30/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Dec 06	Option	1.81	58,233	105,402	369,111	12/08/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Nov 28	Option	19.12	25,000	478,000	315,279	11/30/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Nov 28	Sell	54.61	25,000	1,365,250	290,279	11/30/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Sep 28	Option	16.21	25,000	405,250	315,279	09/30/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Sep 28	Sell	64.77	25,000	1,619,250	290,279	09/30/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Aug 29	Option	16.21	25,000	405,250	315,279	08/31/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Aug 29	Sell	66.92	25,000	1,673,000	290,279	08/31/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jul 27	Option	14.39	25,000	359,750	315,279	07/29/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jul 27	Sell	76.63	25,000	1,915,750	290,279	07/29/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jun 29	Option	12.57	25,000	314,250	315,279	07/01/22
Kulkarni Samarth	Chief Executive Offi.. Chief Executive Officer	Jun 29	Sell	61.87	25,000	1,546,750	290,279	07/01/22